TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, announced the acquisition of Advera Health Analytics, the leader in pharmacovigilance software and data for detection, management, and mitigation of drug safety concerns.
The acquisition of Advera, and its industry-leading Evidex platform, will enable TriNetX clients to gain a complete view of drug safety issues as they happen in real time. The power of Evidex, and the vast real-world data on the TriNetX network, will help life sciences companies refine, manage, and validate safety signals with deep clinical data, and greater efficiency than what the industry has traditionally relied upon.
“Life sciences companies trust Advera for safety signal detection and management,” said Brian M. Overstreet, President and CEO of Advera who will now lead the pharmacovigilance business unit at TriNetX as a senior executive and member of the company’s leadership team. “The Evidex platform enables drug safety teams to quickly validate signals through advanced technology, multiple safety datasets, and integrated workflow management tools. Evidex’s adoption in the market has led to significant progress in the evolution of pharmacovigilance.”
“The combination of TriNetX and Advera brings forth a powerful opportunity for the life sciences community to efficiently evaluate and manage safety signals from traditional pharmacovigilance databases, and then further investigate and refine those signals in context of large and deep clinical real-world data in real time,” said Dr. Jeffrey Brown, Chief Scientific Officer at TriNetX.
“This marriage between Advera and TriNetX creates tremendous potential for growth, and I am thrilled to advance our capabilities to help bring new therapies to market faster, and now safer,” said Gadi Lachman, CEO of TriNetX.
About TriNetX, LLC
TriNetX is a global network of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. Through its self-service, HIPAA, GDPR, and LGPD-compliant platform of federated EHR, datasets, and consulting partnerships